Uses of Ofofacin

Ofofacin is a drug for the treatment of dyslipidemia with the active ingredient Atorvastatin 20mg. So how should Offofacin 20 be used and what problems should be noted?

Ofofacin 20 has the active ingredient Atorvastatin 20mg, which is used to treat a number of blood lipid disorders. Offofacin 20 is a product of Celogen Pharma Pvt., Ltd (India), prepared in film-coated tablet form and packed in a box of 3 blisters x 10 tablets. The active ingredient Atorvastatin in Ofofacin has the effect of lowering blood cholesterol levels. Specifically, Offofacin 20 blocks the production of cholesterol in the liver by inhibiting a cholesterol-producing enzyme, HMG-CoA reductase. Offofacin can lower blood levels of total cholesterol as well as LDL-Cholesterol (a type of "bad" cholesterol that plays a key role in the pathogenesis of coronary heart disease). Targeted LDL-cholesterol control slows plaque progression and may even reverse coronary heart disease. Unlike other active ingredients in this class, Atorvastatin can also reduce blood triglyceride levels, a factor also associated with coronary heart disease.

Offofacin 20 is indicated in the following cases:
In combination with diet to reduce the concentration of Total Cholesterol, LDL-C, Apolipoprotein B, Triglyceride and increase the concentration of HDL-C (a type of cholesterol) good") in the blood in patients with primary hypercholesterolemia, mixed dyslipidemia (types IIa and IIb and hypertriglyceridemia (type IV); treatment of primary dyslipidemia (type III). ; In combination with other lipid-lowering measures to reduce total cholesterol and LDL-C levels in patients with homozygous familial hypercholesterolemia Contraindication of Offofacin 20:
Hypersensitivity With Atorvastatin or other active ingredients of the same class; Patients with advanced liver disease with unexplained persistent elevations of liver enzymes; Pregnant or lactating women should not take Ofofacin 20 .

Offofacin 20 can be used at any time of the day, regardless of the meal, but for the best effect, it should be taken in the evening.
Dosage Ofofacin 20 treatment of hypercholesterolemia (heterozygous familial or non-familial) and mixed dyslipidemia: Initial dose of 10-20mg (1⁄2 to 1 Ofofacin 20 tablet) , drink 1 time per day. If the patient needs a significant reduction in LDL-cholesterol levels (more than 45%) can be started with a dose of 40mg (2 tablets Ofofacin 20). The therapeutic dose range of Atorvastatin is 10-80mg per day.
After initiation and/or dose escalation of Atorvastatin, patients should have their lipid profiles re-evaluated after 2 to 4 weeks for appropriate dose adjustment.
Dosage of Ofofacin for the treatment of homozygous familial hypercholesterolemia is from 10-80 mg/day and should be considered in combination with other lipid control measures Offofacin 20 can be combined with Resin to increase the effectiveness of treatment. treat.
Dosage of Ofofacin in patients with renal impairment: No adjustment needed.

Ofofacin is generally well tolerated, side effects, if any, are mild and transient.
Common side effects of Ofofacin 20 :
Digestive disorders such as constipation, flatulence, indigestion, abdominal pain, vomiting or diarrhea; Nervousness , headache, insomnia or cognitive impairment; Muscle pain, weakness, myasthenia gravis; Increased liver enzymes, increased plasma creatinine phosphokinase levels; Ofofacin 20 may increase blood sugar and HbA1c.

Co-administration of Ofofacin 20 with inhibitors of CYP3A4 enzymes may increase plasma concentrations of Atorvastatin, which in turn leads to an increased risk of muscle side effects and myopathy.
Ofofacin 20 when used in combination with Amiodarone, the maximum dose is 1 tablet / day to limit the risk of rhabdomyolysis. If the patient needs more than 1 tablet of Ofofacin 20 per day to be effective, the doctor may choose other statin drugs (such as pravastatin).
The risk of muscle damage is increased when Offofacin 20 is combined with the following drugs:
Gemfibrozil; Other fibrate cholesterol-lowering drugs; High dose niacin (>1g/day); Colchicine . Concomitant use of Oftofacin 20 with oral antacids containing magnesium and aluminum hydroxide or cholestyramine should be limited because of the potential for a decrease in plasma concentrations of Atorvastatin.
Atorvastatin plasma concentrations will be increased when Ofofacin 20 is co-administered with Digoxin, Erythromycin or Clarithromycin.
Caution should be exercised when Ofofacin 20 is co-administered with oral contraceptives due to the risk of increased effects of oral contraceptives (including side effects).
Ofofacin 20 used with medicines for HIV and hepatitis C may increase the risk of muscle damage and kidney failure leading to kidney failure.

Consider the use of Ofofacin 20 in patients with risk factors for muscle damage. Ofofacin 20 has a risk of causing adverse reactions such as muscle atrophy, myositis, especially in patients with factors such as over 65 years of age, uncontrolled hypothyroidism or kidney disease. Patients should be closely monitored for adverse reactions while taking Ofofacin 20 .
Before treatment with Ofofacin 20 patients need to be ruled out causes of hypercholesterolemia such as poorly controlled diabetes, dysproteinemia, obstructive liver disease, taking certain other drugs or alcoholism.
Carry out the measurement of total cholesterol, LDL-C, HDL-C and triglyceride periodically during the use of Ofofacin 20, with an interval of not less than 4 weeks and adjust the dose according to the patient's response. At the same time, it is necessary to conduct liver enzyme tests before and during treatment with Ofofacin 20.
Consider monitoring blood creatine kinase (CK) levels in the following cases:
Before treatment, a CK test should be performed for the following: impaired renal function, hypothyroidism, history of close or family history of hereditary myopathy, history of myopathy with the use of Atorvastatin or Fibrate, history of liver disease and/or alcohol abuse, over 70 years of age with risk factors for rhabdomyolysis, Patients with high probability of drug interactions and some special subjects. In these cases, the benefits and risks should be weighed before treatment, and the patient is monitored clinically while taking Offofacin 20. If CK test results are > 5 times the upper limit of normal, treatment with Offofacin 20 should not be started; During the treatment with Ofofacin 20 , if the patient has abnormal muscle symptoms such as pain, stiffness or weakness... they must have blood CK test for intervention measures. Patients with elevated ALT or AST should be monitored until abnormalities resolve. If liver enzyme levels rise above 3 times the upper limit of normal, Offofacin 20 should be discontinued.
Use caution when using Offofacin 20 to patients who drink a lot of alcohol or have a history of liver disease.
Treatment with Ofofacin 20 should be discontinued or discontinued when a patient has severe acute symptoms of myopathy or a risk factor for renal failure secondary to paroxysmal globulinuria (eg, severe acute infection, hypotension, blood pressure, major surgery, injuries, electrolyte disturbances, severe endocrine and metabolic disorders, uncontrolled epilepsy...).